First Sublingual Immunotherapy Tablet for House Dust Mite Allergic Rhinitis May Be US-bound
Key clinical point: A safe, effective, and convenient self-administered alternative to allergy shots or symptomatic medications for house dust mite allergic rhinitis may be in the works.
Major finding: A once-daily tablet containing house dust mite extract resulted in a clinically meaningful 17% improvement relative to placebo in a score combining symptomatic improvement and reduced use of rescue medications.
Data source: This pivotal phase III, double-blind, 52-week randomized trial included 1,482 North American adults and adolescents with house dust mite–induced allergic rhinitis with or without conjunctivitis.
Disclosures: The trial was sponsored by Merck and presented by a full-time company employee.
AT 2016 AAAAI ANNUAL MEETING
Merck already has two FDA-approved SLIT tablets developed with ALK on the U.S. market: Grastek, for treatment of grass pollen–induced allergic rhinitis in children and adults, and Ragwitek, for ragweed-induced allergic disease in adults.
The trial was sponsored by Merck and presented by a full-time company employee.
